Carnitine serum levels and levocarnitine administration in multiple sclerosis patients treated with natalizumab

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of neurology 2011-06, Vol.18 (6), p.e63-e64
Hauptverfasser:	Laffon-Pioger, M., Rocher, F., Caruba, C., Cohen, M., Thomas, P., Lebrun, C.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Carnitine - administration & dosage Carnitine - blood Carnitine - deficiency Cohort Studies Fatigue Syndrome, Chronic - blood Fatigue Syndrome, Chronic - drug therapy Fatigue Syndrome, Chronic - etiology Female Humans Immunosuppressive Agents - administration & dosage Immunosuppressive Agents - adverse effects Indexing in process Male Multiple Sclerosis - blood Multiple Sclerosis - complications Multiple Sclerosis - drug therapy Natalizumab Prospective Studies Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!